Abstract
A novel reducible silica monomer, DESSPMA with diethoxysilyl groups for in situ crosslinking to give a lower crosslinking density and greater permeability than the triethoxysilyl-based TESSPMA was developed to realize enhanced therapeutic efficiency.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
